Articles related to Hematology/Oncology

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.

As healthcare moves forward, it’s crucial to balance quantitative data with the nuanced realities of patient experiences. This article explores the impact of the ‘quantitative fallacy’ on patient care and the importance of clinical judgment.

Venous thromboembolism presents a significant challenge in cancer care, with emerging evidence supporting the use of direct oral anticoagulants for improved outcomes. This highlights the evolving landscape of VTE management in oncology, stressing the importance of personalized treatment strategies.

The FDA’s approval of irinotecan liposome with oxaliplatin, fluorouracil, and leucovorin marks a pivotal advancement in first-line treatment options for metastatic pancreatic adenocarcinoma, showcasing a notable increase in overall and progression-free survival rates.

In the fast-evolving landscape of oncology treatment, a new study reveals oncologists’ unique stance on FDA approval processes, emphasizing the importance of timely access to potentially life-saving drugs despite conventional evidentiary standards.

The POLARIX trial reveals polatuzumab vedotin with R-CHP as a promising first-line therapy for DLBCL, showing a 27% reduction in the risk of progression, relapse, or death and a progression-free survival rate of 76.7% at 2 years.